Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Understand what makes a good financial plan and how it can guide your business decisions. Create a plan that drives your success.
23,048 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Bitcoin has fallen about 19% this year, prompting a closer look at three ETF types—spot, futures, and leveraged futur...
A midweek market jolt hit the memory space as a rival unveiled AI driven compression and Sandisk announced a major in...
The Home Depot is rolling out AI-powered planning and project-management tools for professional builders, aiming to s...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
Base, the Coinbase-backed Ethereum Layer 2, is shifting from optimistic rollups to a zero-knowledge-based finality sy...
Gas prices keep rising as markets weigh supply risks, yet there is scant evidence that major oil companies will ramp ...
Investors are watching alarm.com with a focus on how 2026 earnings will unfold. This guide explains the key drivers, ...
Sabre, a travel-technology stalwart, is navigating a recovering travel market and shifting tech spend. This article b...
Paris-based Capital B raises €15.2 million in a private round to buy 182 BTC, expanding its Bitcoin treasury holdings...
As the AI infrastructure boom intensifies, communities push back against giant data centers. Kevin O’Leary’s Stratos ...
Toast stock dip? has investors weighing growth potential against valuation realities. This guide breaks down the fact...